| Literature DB >> 29218230 |
Andreas F Mavrogenis1, Panayiotis D Megaloikonomos1, Vasileios G Igoumenou1, Georgios N Panagopoulos1, Efthymia Giannitsioti1, Antonios Papadopoulos1, Panayiotis J Papagelopoulos1.
Abstract
Spondylodiscitis may involve the vertebral bodies, intervertebral discs, paravertebral structures and spinal canal, with potentially high morbidity and mortality rates.A rise in the susceptible population and improved diagnosis have increased the reported incidence of the disease in recent years.Blood cultures, appropriate imaging and biopsy are essential for diagnosis and treatment.Most patients are successfully treated by conservative means; however, some patients may require surgical treatment.Surgical indications include doubtful diagnosis, progressive neurological deficits, progressive spinal deformity, failure to respond to treatment, and unresolved pain. Cite this article: EFORT Open Rev 2017;2:447-461. DOI: 10.1302/2058-5241.2.160062.Entities:
Keywords: discitis; spinal infection; spondylitis; spondylodiscitis; vertebral osteomyelitis
Year: 2017 PMID: 29218230 PMCID: PMC5706057 DOI: 10.1302/2058-5241.2.160062
Source DB: PubMed Journal: EFORT Open Rev ISSN: 2058-5241
Fig. 1Lateral radiograph of the thoracolumbar spine of a 70-year-old patient with pyogenic spondylodiscitis that originated from an infected pacemaker shows partial collapse of the T11 and T12 vertebral bodies and T11 to T12 disc degeneration.
Fig. 2Sagittal (a) T1-weighted and (b) T2-weighted MRI of the lumbar spine of a 45-year-old patient with spontaneous pyogenic spondylodiscitis showing reduction of the L4 to L5 vertebral disc height and erosion of the adjacent vertebral end-plates.
Fig. 3(a) Lateral radiograph of the thoracic spine, (b) 99mTc-MDP bone scan, (c) sagittal and (d) axial CT, and sagittal (e) T1-weighted and (f) T2-weighted MRI of the spine of an 83-year-old woman with tuberculosis spondylodiscitis showing increased radionuclide uptake and destruction of the T9 to T10 vertebrae.
Summary of the most recent published studies on spondylodiscitis
| Study | Study design | Patients (number) | Type of infection | Positive cultures | Treatment | Antibiotics (duration) | Outcome | Follow-up (mean) |
|---|---|---|---|---|---|---|---|---|
| Hadjipavlou et al[ | RCS | 101 | Pyogenic | 75.5% | Conservative (57.4% required surgical treatment) | 12 weeks | Relapse 2%, failure 0%, mortality 1% | Not given |
| Loibl et al[ | RCS | 105 | Pyogenic (n=102) | 56.2% | Conservative (53.3% required surgical treatment) | Not given | Mortality 12.4% | 31.5 months |
| Legrand et al[ | RCS | 110 | Pyogenic | 72.8% | Conservative (brace, 89.1%) | 103 days | Mortality 1% | 3 months |
| Parra et al[ | RCS | 108 | Pyogenic (n=67) | 69.4% | Conservative (25% required surgical treatment) | 5.2 weeks IV | Mortality 10% | 73 months |
| Mulleman et al[ | RCS | 136 | Pyogenic | 100% | Conservative (brace, 74%; 8.9% required surgical treatment) | 122 days | Mortality 4.6% | Not given |
| Kotil et al[ | PCS | 44 | TB | 100% | Conservative (4.6% required surgical treatment) | 17 months | Favorable 95.4% | 24 months |
| Hassan et al[ | RCOMPS | 42 | TB | Not given | Surgical (anterior, n=20; posterior, n=22) | At least 2 weeks before and at least 9 months after surgery | Not given | 15 months |
| Park et al[ | RCS | 116 | TB | 88.3% | Conservative (84.4% required surgical treatment) | 6-9 months (n=20) vs > 12 months (n=96) | Favorable 70% vs. 83.3% | Not given |
| Jensen et al[ | RCS | 133 | Pyogenic | 40% | Conservative | 2 to >10 weeks | Relapse 10%, failure 14%, mortality 14% | Not given |
| Shi et al[ | RCS | 967 | TB | 100% | Conservative (76.5% required surgical treatment) | Not given | Relapse 0.6%, failure 0%, mortality 0% | Not given |
| Aagaard et al[ | RCS | 100 | Pyogenic | 90% | Conservative (41% required surgical treatment) | 91 days | Relapse 4%, failure 0%, mortality 8% | 12 months |
| Roblot et al[ | RCOMPS | 120 | Pyogenic (n=98), | 100% | Conservative | <6 weeks (n=36) vs. >6 weeks (n=84) | Relapse 0%, mortality 8% vs. relapse 7.1%, mortality 12% | 6 months (n= 120), 41 months (n= 91) |
| Bernard et al[ | RCT | 351 | Pyogenic | 100% | Conservative | 6 weeks (n=176) vs.12 weeks (n=175) | Relapse 2.3%, failure 9.1%, mortality 8% vs. relapse 0%, failure 9.1%, mortality 7% | 12 months |
| Valancius et al[ | RCOMPS | 196 | Pyogenic | 72.9% | Conservative (n=91) and surgical (n=105) | At least 2 weeks IV and 3–6 months per os | Relapse 7.6%, failure 13.1%, mortality 8.7% vs. relapse 2.9%, failure 0%, mortality 1.9% | 12 months |
| Rossbach et al[ | RCS | 135 | Pyogenic (n=127) | 59.5% | Conservative (brace) and surgical (n=75) | Not given | Not given | Not given |
| Si et al[ | PCOMPS | 23 | Pyogenic | Not given | Surgical (anterior, n=12; posterior fusion, n=11) | Not given | Relapse 0%, failure 0% vs. relapse 0%, failure 0% | 38 months |
| Pee et al[ | RCOMPS | 60 | Pyogenic | 50% | Surgical (anterior cages and pedicle screw fixation, n=37; anterior struts and pedicle screw fixation, n=23) | At least 6 weeks IV and at least 6 weeks per os | Infection resolution in all patients | 35.8 months |
| Vcelak et al[ | RCOMPS | 31 | Pyogenic (n=27) | 100% | Surgical (dorsal transmuscular, n=23; two-stage posterior-anterior, n=8) | Not given | Relapse 8.7%, failure 4.3%, mortality 4.3% vs relapse 0%, failure 0%, mortality 0% | 12 months |
| Ozturk et al[ | RCOMPS | 56 | Pyogenic (n=40) | 100% | Surgical (sequential, n=29; simultaneous anterior and posterior surgery, n=27) | 6 weeks IV and 3 months per os (pyogenic) | Failure 0% | 78 months |
| Lee et al[ | RCOMPS | 26 | Pyogenic (n=24), | 42% | Surgical (transpedicular curettage and drainage, n=10; combined anterior-posterior approach, n=26) | 91.1 days vs 65 days | Relapse 10%, failure 0%, mortality 0% vs | 57 months |
| Nasto et al[ | RCOMPS | 27 | Pyogenic | 100% | Conservative (brace, n=15) and surgical (n=12) | 76-84 days | Relapse 0%, failure 0%, mortality 0% | 9 months |
| Lin et al[ | RCOMPS | 45 | Pyogenic | 84% | Surgical (combined anterior-posterior, n=25; combined anterior-percutaneous posterior, n=20) | 28-83 days | Relapse 8%, mortality 0% vs relapse 5%, mortality 0% | 24 months |
| Karadimas et al[ | RCS | 163 | Pyogenic (n=141) | 59% | Conservative (brace, n=70) and surgical (without, n=56; with instrumentation, n=37) | 2-7 months | Failure 0 %, mortality 11.4% vs. failure 12.5%, mortality 13.5% | 12 months |
| Pourtaheri et al[ | RCOMPS | 104 | Pyogenic | Not given | Surgical (instrumented, n=57; non-instrumented, n=47) | Not given | Infection resolution 54%, mortality 9% vs. infection resolution 42.5%, mortality 17% | 43 months |
| Schomacher et al[ | RCOMPS | 37 | Pyogenic | 70.3% | Surgical (PEEK cages, n=21; titanium cages, n=16) | 2–4 weeks IV, 8–10 weeks per os | Reinfection was not observed in any patient | 20.4 months |
| Chen et al[ | RCS | 24 | 100% | Surgical (posterior debridement, bone grafting and instrumentation) | 6.5 months | Infection resolution | 14.3 months | |
| Linhardt et al[ | RCT | 22 | Pyogenic (n=17) | Not given | Surgical (ventro-dorsal spondylodesis, n=20; ventral spondylodesis, n=10) | 23.8-24.1 weeks | Relapse 8 %, failure 0%, mortality 25% vs relapse 0%, failure 0%, mortality 10% | 63 months |
Note: TB: tuberculosis; RCS: retrospective case series; RCT: randomized controlled trial; RCOMPS: retrospective comparative study; PCS: prospective cohort study; PCOMPS: prospective comparative study; PEEK: polyether ether ketone